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Deoxysugars are prevalent structural components of many an-
tibiotics and often contribute substantially to their biological
properties.[1–3] Methylation of hydroxy group(s) on the deoxy-
sugar ring is relatively common (Figure 1), as O-methylation
not only protects the reactive hydroxy group from undesired
modifications, such as oxidation or dehydration, but also alters
the solubility and pharmacokinetic properties of the resulting
molecule.[4] Biosynthetically, these O-methylation reactions are
mainly catalyzed by a variety of S-adenosyl-l-methionine (SAM
or AdoMet)-dependent methyltransferases in a site-specific
manner. For example, the two SAM-dependent O-methyltrans-
ferases TylE and TylF in the tylosin biosynthetic pathway of
Streptomyces fradiae sequentially methylate individual hydroxy
groups (C2’’’-OH and C3’’’-OH) in the 6-deoxyallose moiety of
demethylmacrocin to generate the macrolide antibiotic tylo-
sin.[5–8] ElmMI, ElmMII, and ElmMIII are responsible for the con-
secutive methylation of three hydroxy groups of l-rhamnose in
the antitumor polyketide antibiotic elloramycin.[9] Moreover, a
growing number of O-methyltransferases involved in various
deoxysugar methylation reactions such as EryG,[10] OleY,[11]
SpinH, SpinI, and SpinK[12] have been reported in diverse anti-ACHTUNGTRENNUNGbiotic biosynthetic systems.
Mycinamicins represent a family of macrolide antibiotics
with more than 20 members produced by the rare actinomy-
cete Micromonospora griseorubida.[13–15] The antibacterial activi-
ties of some mycinamicin products against Staphylococcus
aureus are higher than those of the clinical macrolide antibiot-
ics erythromycin and leucomycin. More importantly, mycinami-
cins have shown strong activity against a number of antibiotic-
resistant human pathogens.[13] Structurally, the major mycina-
micin products of wild-type strain M. griseorubida A11725,ACHTUNGTRENNUNGincluding mycinamicins I, II, IV, and V, are composed of a 16-
membered ring macrolactone core, an N,N-dimethylated deox-
ysugar desosamine, and a di-O-methylated deoxyhexose myci-
nose (Figure 1). During the past two decades, the biosynthesis
of mycinamicin has been elucidated through strain mutagene-
sis, bioconversion studies,[16, 17] and sequence analysis of the
complete mycinamicin gene cluster,[18] wherein two putative O-
methyltransferase genes mycE and mycF were tentatively as-
signed.
Initial bioinformatics analysis of the corresponding genes re-
vealed that MycE and MycF show high amino acid sequence
similarities to TylE (demethylmacrocin O-methyltransferase)
and TylF (macrocin O-methyltransferase), respectively, in theACHTUNGTRENNUNGtylosin biosynthetic pathway.[18] Accordingly, the function of
MycE was proposed to methylate the C2’’-OH group of 6-
deoxy ACHTUNGTRENNUNGallose in mycinamicin VI, leading to mycinamicin III,
whereas MycF was presumed to transfer a methyl group to the
C3’’-OH group of javose (that is, C2’’-methylated 6-deoxyallose)
in mycinamicin III to generate mycinamicin IV (Scheme 1). The
proposed functions of MycE and MycF were supported by in
vivo precursor feeding studies.[16, 19] Herein, we report the ex-
pression of mycE and mycF in Escherichia coli, and purification
of MycE and MycF to establish their biochemical function forACHTUNGTRENNUNGregiospecific deoxysugar O-methylation in mycinamicin macro-
lide antibiotics.
Comparative analysis revealed that MycE (399 amino acids)
is significantly larger than MycF (222 amino acids). Alignment
of these two O-methyltransferases exhibits low sequence iden-
tity (11.3 %), suggesting they might have evolved from distinct
ancestors. A protein BLAST search revealed a number of O-
methyltransferases with either MycE or MycF as the query pro-
tein. Interestingly, all candidates with high sequence similarities
are O-methyltransferases involved in deoxysugar biosynthesis.
In the phylogenetic tree (Figure 2 A) of selected O-methyltrans-
ferases with high similarities to MycE and MycF, it is evident
that they are located in distinct branches; this indicates their
potentially disparate evolutionary origins. In the sequence
alignment of MycE with corresponding close relatives (Fig-
ure 2 B and C), three conserved motifs (motifs I–III)[9, 20] were
identified that are predicted to contribute to SAM binding. In
contrast, there are only two conserved SAM binding motifs
(motifs I and III) found in MycF.
To confirm the proposed function of MycE and MycF, we
cloned mycE and mycF genes into pET28b for overexpression
in E. coli BL21 (DE3). The recombinant N-terminal His6-tagged
proteins were purified to homogeneity by one-step Ni-NTA
agarose chromatography (Figure 3). With the purified enzymes
in hand, we initially tested the activities of MycE and MycF in
sodium phosphate buffer (50 mm, pH 7.4) at 30 8C using SAM
as methyl donor and mycinamicin VI and mycinamicin III as
substrates (Scheme 1). MycE was unreactive toward both sub-
strates, whereas MycF was able to moderately methylate myci-
namicin III (but not VI), forming mycinamicin IV (data not
shown). Because the dependence of this class of methyltrans-
ferases on a metal cofactor is not uncommon, we next investi-
gated the effect of various divalent metal ions on the activities
of MycE and MycF. Both enzymes achieved optimal activity in
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the presence of 10 mm MgCl2 (Figure 4 A). A number of alter-
native divalent ions including Co2 + , Fe2 + , Mn2+ , and Zn2+ are
capable of supporting suboptimal activities. Interestingly, the
Mg2 + dependence of MycE appears to be more pronounced
than MycF, as MycF remained moderately active in the absence
of Mg2+ . The metal dependence of MycF was further assessed
by the addition of 2 mm of EDTA; however, this treatment
failed to abrogate activity, suggesting that a metal ion might
be dispensable in the O-methyltransferase reaction catalyzed
by MycF. In contrast, EDTA significantly lowered the activity of
MycE even in the presence of 10 mm Mg2+ . The optimal pH
and temperature range for MycE and MycF assays were deter-
mined through comparison of enzymatic activities under vari-
ous reaction conditions. The optimal reaction conditions of the
two O-methyltransferases is pH 9.0 (Figure 4 B), significantly
higher than the corresponding homologues TylE (optimal
pH 7.5–8.5) and TylF (pH 7.5–8.0).[7] At pH 9.0, the maximalACHTUNGTRENNUNGactivities of MycE and MycF were observed at 50 and 37 8C
(Figure 4 C), respectively, higher than those of TylE (42 8C) and
TylF (31 8C).[7]
Under optimal conditions, the in vitro activities of MycE and
MycF were analyzed to reveal that MycE methylated the C2’’-
OH of 6-deoxyallose, converting a majority of mycinamicin VI
to mycinamicin III (Figure 5 B). MycE was incapable of double
methylation to generate mycinamicin IV. The second C3’’-OH
methylation of javose was catalyzed by MycF, with a higher
Figure 1. Antibiotics containing various O-methylated deoxysugars. The methyl groups installed by O-methyltransferases are numbered.
Scheme 1. Physiological reactions catalyzed by MycE and MycF.
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conversion than MycE toward mycinamicin VI (Figure 5 F). Co-
incubation of MycE and MycF with starting substrate mycina-
micin VI resulted in the accumulation of both mycinamicins III
and IV (Figure 5 D). Notably, mycinamicin IV cannot be further
methylated by these two methyltransferases, despite the re-
maining hydroxy group at the C4’’ position in mycinose. Col-
lectively, it is evident that both MycE and MycF possess high
substrate specificity.
Finally, we determined the steady-state kinetic parameters
(Table 1) for MycE and MycF based on substrate consumption
monitored by HPLC. MycE converted mycinamicin VI to myci-
namicin III with a KM value of 26.47.0 mm and a kcat value of
5.00.5 min1. In contrast, MycF methylated mycinamicin III
approximately twofold more efficiently (with respect to kcat/KM
value) than MycE toward mycinamicin VI. Notably, these kinetic
data for MycE and MycF are similar to those of TylE and TylF in
the tylosin pathway, as previously reported.[7]
The mycinamicin post-PKS (polyketide synthase) tailoring
pathway includes two glycosylation steps mediated by two
glycosyltransferases (MycB and MycD), four oxidation steps
mediated by two cytochrome P450 monooxygenases (MycCI
and MycG), and two methylation steps catalyzed by MycE and
MycF.[16] These post-PKS modifications not only lead to struc-
tural diversification, but also confer biologically active proper-
ties on the resulting metabolites. We recently confirmed all oxi-
dative tailoring steps in vitro through functional analysis of
two P450 enzymes.[21] This work revealed the importance of
both methylation steps in 6-deoxyallose for substrate recogni-
tion by the MycG monooxygenase. In this study, we have ad-
vanced the knowledge about this pathway by analyzing MycE
and MycF O-methyltransferases in vitro. Taking advantage of
the reconstituted optimal in vitro assay, the substrate specifici-
ty of MycE and MycF and hence the order of sugar modifica-
tion (mycinamicin VI!III!IV) in this pathway was unambigu-
ously determined. This new information will help facilitate
future efforts to manipulate deoxysugar biosynthesis for gener-
ation of novel macrolide antibiotics.
Experimental Section
MycE and MycF gene cloning : Using cosmid pMR01[18] as tem-
plate, mycE and mycF genes were amplified by PCR under standard
conditions with primers as follows: forward, 5’-GGA GTT CCA TAT
GAC CGC ACA GAC CGA A-3’ for mycE and 5’-GGA GTT CCA TAT
GAG CCC GTC GAC CGG A-3’ for mycF (bases in italics represent
the NdeI cutting site); reverse, 5’-ACA TCA AGC TTT CAT GTC GCG
CCT CCG GA-3’ for mycE and 5’-ACA TCA AGC TTT CAG GCC GAG
CGA CGC CA-3’ for mycF (underlined bases indicate the HindIII re-
striction site). The gel-purified cDNAs were double digested by
NdeI and HindIII (New England Biolabs), followed by the ligation of
fragments containing mycE and mycF genes into NdeI/HindIII-treat-
Figure 2. Amino acid sequence analysis of MycE and MycF. A) Phylogenetic
tree of selected O-methyltransferases generated by MegAlign (DNASTAR)
with the Clustal W method. MycE and MycF are highlighted in bold and
italic. The selected O-methyltransferases include MycE and MycF (mycinami-
cin pathway), TylE and TylF (tylosin pathway), ChmMI and ChmMII (chalco-
mycin pathway), SpnH, SpnI, and SpnK (spinosad pathway), BusH, BusI, and
BusK (butenyl spinosyn pathway), SnogY (nogalamycin pathway), OleY (ole-
andomycin pathway), ElmMI, ElmMII, and ElmMIII (elloramycin pathway),
NovP (novobiocin pathway), CumN (coumermycin pathway), and MtfB (my-
cobacterial serovar-specific glycopeptidolipid pathway). B) SAM binding
motifs of MycE and its homologues. C) SAM binding motifs of MycF and its
homologues.
Figure 3. SDS-PAGE analysis of purified MycE and MycF.
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ed pET28b (Novagen) to generate recombinant plasmids pET28b-
mycE and pET28b-mycF for the expression of N-terminal His6-
tagged MycE and MycF, respectively. The identity of the inserted
gene was confirmed by nucleotide sequencing.
Protein expression and purification : Recombinant plasmids
pET28b-mycE and pET28b-mycF were used to transform E. coli
BL21 (DE3) cells with a Z-CompetentTM Kit (Zymo Research). The re-
sulting transformants were grown at 37 8C in 1 L of LB broth con-
taining kanamycin (50 mg mL1) for 2–3 h until OD600 reached 0.6–
0.8. Isopropyl-b-d-thiogalactopyranoside (IPTG) was then added to
a final concentration of 0.1 mm to induce gene expression, and the
cells were cultured at 18 8C overnight. The culture was centrifuged
Figure 4. Optimization of methylation reactions catalyzed by MycE and
MycF. Effects of A) divalent metal ion, B) pH, and C) temperature.
Figure 5. LC–MS analysis (l = 280 nm) of in vitro conversions catalyzed by
MycE and MycF. A) Mycinamicin VI (M-VI) standard; B) M-VI + MycE; C) M-
VI + MycF; D) M-VI + MycE + MycF; E) mycinamicin III (M-III) standard; F) M-
III + MycF; G) M-III + MycE; H) mycinamicin IV (M-IV) standard. Compound
identity was confirmed by mass spectrometry and comparison with standard
compound regarding retention time and co-injection.
Table 1. Steady-state kinetic parameters of MycE and MycF.
KM [mm] kcat [min
1] kcat/KM [mm
1 min1]
MycE 26.47.0 5.00.5 0.19
MycF 30.76.9 13.51.1 0.44
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at 5000 g for 10 min to collect cells. The freeze–thaw cell pellet was
resuspended in 30 mL of lysis buffer (50 mm NaH2PO4, 300 mm
NaCl, 10 mm imidazole, 10 % glycerol, pH 8.0) and applied to soni-
cation. Cell debris was removed by centrifugation at 35 000 g for
30 min, and the supernatant was mixed with 1 mL of Ni-NTA agar-
ose (Qiagen) for 1 h at 4 8C. The slurry was loaded onto an empty
column, and the column was washed stepwise with 10 mL of lysis
buffer and 40–60 mL of wash buffer (50 mm NaH2PO4, 300 mm
NaCl, 20 mm imidazole, 10 % glycerol, pH 8.0). The bound His6-
tagged proteins were eluted with elution buffer (50 mm NaH2PO4,
300 mm NaCl, 250 mm imidazole, 10 % glycerol, pH 8.0). The MycE
(~45 kDa) and MycF (~30 kDa) proteins were further purified and
concentrated with 30 kDa and 10 kDa size-exclusion filters
(Amicon), respectively. The final desalting step was attained by
buffer exchange into storage buffer (50 mm NaH2PO4, 10 % glycer-
ol, pH7.4) with a PD-10 column (GE Healthcare).
Enzyme assays : The optimized enzyme assay was carried out in
100 mL of 50 mm Tris-buffer (pH 9.0) containing 2 mm MycE or
MycF, 250 mm substrate (mycinamicin VI for MycE or mycinamicin III
for MycF), 10 mm MgCl2, and 500 mm SAM at 50 8C (for MycE) or
37 8C (for MycE) for 1 h. The reactions were quenched by extraction
with CHCl3 (2  200 mL). The resulting organic extracts were dried
and redissolved in 120 mL methanol. LC–MS analysis of the reaction
extract was performed with an LC–MS-2010 EV instrument (Shi-
madzu) by using an XBridgeTM reversed-phase HPLC column (C18,
3.5 mm, 150 mm; Waters) under the following conditions: 20!
100 % solvent B over 18 min (solvent A = deionized H2O + 0.1 %
formic acid; solvent B = CH3CN + 0.1 % formic acid), flow rate:
0.2 mL min1, UV wavelength: 280 nm.
Steady-state kinetics : The standard reaction buffered with 50 mm
Tris-HCl (pH 9.0) contained 0.3 mm MycE or MycF, 500 mm MgCl2, 2–
100 mm mycinamicin VI for MycE or 3–100 mm mycinamicin III in a
total volume of 396 mL. After pre-incubation at optimal tempera-
ture for 5 min, the reactions with various substrate concentrations
were initiated by adding 4 mL of SAM (50 mm), and three aliquots
(100 mL) were taken at three time points (0, 1, 2 min and 0, 2,
4 min for reactions with substrate concentrations <40 mm and
>60 mm, respectively) within the linear range to thoroughly mix
with 100 mL of methanol for reaction termination. The proteins
were removed by centrifugation at 16 000 g for 15 min. The super-
natant was subject to HPLC analysis to monitor substrate con-
sumption within the linear range, thereby deducing the initialACHTUNGTRENNUNGvelocity of the O-methylation reaction. The HPLC conditions were:
XBridgeTM reversed-phase HPLC column (C18, 5 mm, 250 mm;
Waters) 20!100 % solvent B over 20 min (solvent A = deionized
H2O + 0.1 % trifluoroacetic acid; solvent B = CH3CN + 0.1 % tri-
fluoroacetic acid), flow rate: 1.0 mL min1, UV wavelength: 280 nm.
All measurements were performed in duplicate, and velocities de-
termined under different substrate concentrations were fit into the
Michaelis–Menten equation to calculate the kinetic parameters.
Acknowledgements
This work was supported by NIH grant GM078 553 and the
Hans W. Vahlteich Professorship to D.H.S.
Keywords: antibiotics · biosynthesis · deoxysugars ·
mycinamicin · O-methyltransferases
[1] C. J. Thibodeaux, C. E. Melancon, H.-w. Liu, Nature 2007, 446, 1008–
1016.
[2] A. Trefzer, J. A. Salas, A. Bechthold, Nat. Prod. Rep. 1999, 16, 283–299.
[3] A. C. Weymouth-Wilson, Nat. Prod. Rep. 1997, 14, 99–110.
[4] C. Zubieta, X. He, R. A. Dixon, J. P. Noel, Nat. Struct. Biol. 2001, 8, 271–
279.
[5] R. Fouces, E. Mellado, B. Diez, J. L. Barredo, Microbiology 1999, 145,
855–868.
[6] N. J. Bauer, A. J. Kreuzman, J. E. Dotzlaf, W. K. Yeh, J. Biol. Chem. 1988,
263, 15 619–15 625.
[7] A. J. Kreuzman, J. R. Turner, W. K. Yeh, J. Biol. Chem. 1988, 263, 15 626–
15 633.
[8] N. Bate, E. Cundliffe, J. Ind. Microbiol. Biotechnol. 1999, 23, 118–122.
[9] E. P. Patallo, G. Blanco, C. Fischer, A. F. Brana, J. Rohr, C. Mendez, J. A.
Salas, J. Biol. Chem. 2001, 276, 18765–18774.
[10] T. J. Paulus, J. S. Tuan, V. E. Luebke, G. T. Maine, J. P. DeWitt, L. Katz, J.
Bacteriol. 1990, 172, 2541–2546.
[11] I. Aguirrezabalaga, C. Olano, N. Allende, L. Rodriguez, A. F. Brana, C.
Mendez, J. A. Salas, Antimicrob. Agents Chemother. 2000, 44, 1266–1275.
[12] C. Waldron, P. Matsushiba, P. R. Rosteck, M. C. Broughton, J. Turner, K.
Madduri, K. P. Crawford, D. J. Merlo, R. H. Baltz, Chem. Biol. 2001, 8, 487–
499.
[13] I. Satoi, N. Muto, M. Hayashi, T. Fujii, M. Otani, J. Antibiot. 1980, 33, 364–
376.
[14] K. Kinoshita, S. Takenaka, H. Suzuki, T. Morohoshi, M. Hayashi, J. Antibiot.
1992, 45, 1–9.
[15] K. Kinoshita, S. Takenaka, M. Hayashi, J. Antibiot. 1991, 44, 1270–1273.
[16] H. Suzuki, S. Takenaka, K. Kinoshita, T. Morohoshi, J. Antibiot. 1990, 43,
1508–1511.
[17] Y. Anzai, Y. Ishii, Y. Yoda, K. Kinoshita, F. Kato, FEMS Microbiol. Lett. 2004,
238, 315–320.
[18] Y. Anzai, N. Saito, M. Tanaka, K. Kinoshita, Y. Koyama, F. Kato, FEMS Mi-
crobiol. Lett. 2003, 218, 135–141.
[19] M. Inouye, H. Suzuki, Y. Takada, N. Muto, S. Horinouchi, T. Beppu, Gene
1994, 141, 121–124.
[20] R. M. Kagan, S. Clarke, Arch. Biochem. Biophys. 1994, 310, 417–427.
[21] Y. Anzai, S. Li, M. R. Chaulagain, K. Kinoshita, F. Kato, J. Montgomery,
D. H. Sherman, Chem. Biol. 2008, 15, 950–959.
Received: February 18, 2009
Published online on May 4, 2009
ChemBioChem 2009, 10, 1297 – 1301  2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.chembiochem.org 1301
